Mitek aka DePuy synthes sports

Quote

orthopt

Guest
Will dePuy synthes sports (formerly Mitek?) survive. Market share is terrible. Brand new leadership is clueless. Pipeline non-existent. Commissions have been halved. Will this be the next medtech spin-off?
 




MITEK must have sunk below 10% share, it's no longer a credible player in SportsMed, will never compete against Arthrex, S&N, Stryker.
Divestment was explored in 2016 but no one was interested in buying low share and no pipeline.
A group of long term MITEK employees, the final ones with market understanding and customer relationships were all let go at the start of the year, shows DPS has pretty much given up on Sports.
With Joints declining, a lacklustre robot and DePuy Spine long dead the old Synthes Trauma business is the only part of DePuy with any prospects for growth.
J&J Medtech do not have the stomach or the talent to win in Ortho.
 


anonymous said:
MITEK must have sunk below 10% share, it's no longer a credible player in SportsMed, will never compete against Arthrex, S&N, Stryker.
Divestment was explored in 2016 but no one was interested in buying low share and no pipeline.
A group of long term MITEK employees, the final ones with market understanding and customer relationships were all let go at the start of the year, shows DPS has pretty much given up on Sports.
With Joints declining, a lacklustre robot and DePuy Spine long dead the old Synthes Trauma business is the only part of DePuy with any prospects for growth.
J&J Medtech do not have the stomach or the talent to win in Ortho.
Click to expand...

What is Spine’s share?
 



Write your reply...
Top Bottom
Back
Quote